Comparing immunoadsorption and immunoglobulins for treating CIDP
Official title: Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Run by University of Ulm · NCT04881682 · Data updated 2026-11-12
This study is testing whether a new treatment called immunoadsorption works better than immunoglobulin for people with CIDP who haven't improved with other medications.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | University of Ulm Academic / other |
| Locations | 1 site (Ulm, Baden-Wurttemberg) |
| Status | Recruiting |
| Started | May 1, 2023 |
| Main results expected | September 1, 2027 |
| Study ends | March 1, 2028 |
| Registry record updated | May 1, 2026 |
| Trial ID | NCT04881682 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older with a diagnosis of CIDP and insufficient response to methyl-prednisolone.
✕Probably not a fit
Patients with active systemic infections or those who have contraindications to immunoadsorption or immunoglobulin therapy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial is a randomized controlled study that evaluates the safety and efficacy of repeated immunoadsorption compared to immunoglobulin treatment in patients with steroid-refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The study focuses on individuals diagnosed with CIDP who have not responded adequately to previous treatment with methyl-prednisolone. Participants will be monitored for their response to the two different treatment approaches over the course of the trial.
Why it matters
Potential benefit: If successful, this study could provide a more effective treatment option for patients with CIDP who do not respond to standard therapies.
How similar studies have gone: While there have been studies on immunoglobulins for CIDP, the specific comparison of immunoadsorption versus immunoglobulins in this context is a novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of possible, probable, or definite CIDP (typical or atypical) according to European Federation of Neurological Societies (EFNS) guidelines * Disease duration of 3 years or less * Age 18 years or above * Previous treatment with methyl-prednisolone and insufficient therapeutic response as judged by the treating physician, or contraindications against methyl-prednisolone, or clinically significant side effects under methyl-prednisolone therapy as judged by the treating physician Exclusion Criteria: * Clinical or laboratory evidence of manifest systemic infection, i.e., C-reactive protein (CRP) above 20 mg/l, or evidence of nitrite-positive urinary tract infection * Intake of angiotensin converting enzyme inhibitor within 1 week before first treatment * immunoglobulin A deficiency * Other contraindications against immunoadsorption or intravenous immunoglobulins
Where it's running
-
Department of Neurology, University of Ulm
Ulm, Baden-Wurttemberg, Germany Recruiting
Study contacts
- Principal investigator: Johannes Dorst, Prof — University of Ulm
- Study coordinator: Johannes Dorst, Prof
- Email: johannes.dorst@uni-ulm.de
- Phone: +49 731 177 5285
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Real-world efgartigimod use in adults with CIDP
This study will see if efgartigimod helps adults with CIDP when given as part of routine clinical care.
-
Empasiprubart for adults with CIDP
This study will test whether IV empasiprubart helps improve symptoms and is safe for adults with CIDP, with an initial 24-week randomized comparison to placebo followed by two years of empasiprubart for all participants.
-
Empasiprubart versus IVIg for treating CIDP in adults
This trial tests whether empasiprubart works as well as IVIg and is safe for adults with CIDP who currently benefit from IVIg.
-
Using rituximab to achieve remission in patients with chronic inflammatory demyelinating polyneuropathy
This study is testing if rituximab can help people with chronic inflammatory demyelinating polyneuropathy feel better and reduce their need for other treatments.
-
Comparing IVIG and SCIG dosing for CIDP
This trial will test whether body composition changes how IVIG and SCIG deliver protective antibodies in adults with CIDP.
-
Collecting blood samples from patients undergoing plasma exchange
This study is collecting blood samples from patients with immune-related diseases who are having plasma exchange to see how their antibody levels change during treatment and to use the samples for future research.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.